FDA’s Biosimilar Guidances Win Praise For High Hurdles, Flexibility
Merck Bioventures and Hospira execs say the draft guidances are consistent with their approach to biosimilars development. One attorney says FDA’s broad and flexible approach will require the agency to be careful to ensure a level playing field for sponsors.
You may also be interested in...
The agency’s first three draft guidances on biosimilar product development describe how to characterize biosimilar and reference products and extrapolate data on one condition of use to another. FDA says interchangeability is difficult to determine now and will require a switching study.
The apparently first-ever FDA press release for an advertising warning letter underscores importance of opioid issues – and the agency’s changing approach to media relations in general. FDA objects to Alkermes journal ad that excludes risk information about its opioid dependence treatment drug.
Revised North American trade deal touted as enabling Congress to address crisis of high drug prices; requirement for 10 years biologic exclusivity is removed and language to allow incentives for generics added.